Back

CD44---targeted rosuvastatin delivery attenuates valvular fibrotic remodelling in calcific aortic valve disease

29 August 2026 (14:50 - 15:00)
Organised by: Logo
Congress Presentation Part of: Molecular and genetic basis for aortic valve disease Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Xiao Hang Yuan

Beijing (China)

5 More presentations in this session

Presentation thumbnail
One locus, three phenotypes: LPA as the common genetic driver of early aortic valve calcification, coronary artery calcification and carotid plaque
Doctor A. Wang Gottlieb (Stockholm, SE)
Abstract Slides
Presentation thumbnail
ACKR1-high endothelial cells enhance CXCL8 responsiveness and reveal a therapeutic entry point in calcific aortic valve disease
Doctor X. Guo (Beijing, CN)
Abstract Slides
Presentation thumbnail
Disruption of the basement membrane underlies common pathogenesis of valvular heart diseases revealed by a pan-valvular single-cell atlas
Doctor H. Shi (Wuhan, CN)
Abstract Slides
Presentation thumbnail
Hsp90α attenuates calcific aortic valve disease by upregulation HIF-1α and suppressing VIC osteogenesis
Professor Y. Chen (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Spatiotemporal dynamics of interleukin 6 in calcific aortic valve disease: a multi-omics and translational study
Doctor S. Shu (Beijing, CN)
Abstract Slides

Access the full session

Session thumbnail
Molecular and genetic basis for aortic valve disease
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 14:50 CET
You may be interested in
thumbnail
Congress Presentation
CXCL12/ACKR3 chemokine axis: a molecular regulator of aortic valve homeostasis and pathology
30 August 2025
thumbnail
Congress Presentation
Non-clinical evaluation of YN001-a promising drug for atherosclerotic therapy by targeted delivery system
25 August 2023
thumbnail
Congress Session
Innovations in structural heart and coronary interventions: imaging, artificial intelligence, and procedural optimisation
29 August 2026
thumbnail
Congress Session
Novel drugs for cardiovascular diseases
1 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources